The exploration of SN-38 role in combination with other immunotherapy modalities, such as PD-1/PD-L1 inhibitors, continues to evolve, signaling new directions that could redefine the therapeutic landscape in these cancer types [37]. This evidence concerns the gene CD274 and cancer.